About: covid:PMC7347351

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: covid:PMC7347351 Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
Creator	Muntoni, Francesco Kirschner, Janbernd Butoianu, Nina Goemans, Nathalie Haberlova, Jana Kostera-Pruszczyk, Anna Mercuri, Eugenio Quijano-Roy, Susana Sejersen, Thomas Servais, Laurent Tizzano, Eduardo Ziegler, Andreas van der Pol, W.
is schema:about of	named entity 'gene' named entity 'genetic confirmation' named entity 'clinical trial' named entity 'gene therapy' named entity 'SMA' named entity 'copy number' named entity 'intravenous' named entity 'risk ratio' named entity 'gene' named entity 'Biogen' named entity 'SMN2' named entity 'EMA' named entity 'Roche' named entity 'nusinersen' named entity 'advanced stages' named entity 'mutation' named entity 'SMA' named entity 'oligonucleotide' named entity 'Spinal muscular atrophy' named entity 'disease-modifying' named entity 'advanced stages' named entity 'treatment of patients' named entity 'SMA' named entity 'SMA' named entity 'Risdiplam' named entity 'copy numbers' named entity 'SMA' named entity 'newborn screening' named entity 'SMA' named entity 'type 1' named entity 'European Medicine Agency' named entity 'motor neurons' named entity 'Biogen' named entity 'route of administration' named entity 'dorsal ganglia' named entity 'evolution' named entity 'intrathecally' named entity 'copy number' named entity 'SMN2' named entity 'biodistribution' named entity 'risk-benefit ratio' named entity 'disease outcome' named entity 'Avexis' named entity 'clinical trials' named entity 'Roche' named entity 'SMA' named entity 'AveXis' named entity 'Biogen' named entity 'SMA' named entity 'viral vector' named entity 'muscle weakness' named entity 'health systems' named entity 'protein expression' named entity 'copy number' named entity 'SMA' named entity 'Avexis' named entity 'SMA' named entity 'nusinersen' named entity 'clinical trials' named entity 'bi-allelic' named entity 'clinical diagnosis' named entity 'newborn screening' named entity 'SMN' named entity 'Roche' named entity 'Biogen' named entity 'long-term' named entity 'biomarkers' named entity 'clinical diagnosis' named entity 'SMA' named entity 'gene therapy' named entity 'SMN1' named entity 'Avexis' named entity 'body weight' named entity 'SMA' named entity 'AveXis' named entity 'REDCap' named entity 'type 1' named entity 'shared decision making' named entity 'SMA' named entity 'Onasemnogene abeparvovec' named entity 'SMN1' named entity 'body weight' named entity 'Nusinersen' named entity 'Palliative care' named entity 'disability' named entity 'pharmaceutical industry' named entity 'SMN2'

Attributes

Values

Creator

Muntoni, Francesco
Kirschner, Janbernd
Butoianu, Nina
Goemans, Nathalie
Haberlova, Jana
Kostera-Pruszczyk, Anna
Mercuri, Eugenio
Quijano-Roy, Susana
Sejersen, Thomas
Servais, Laurent
Tizzano, Eduardo
Ziegler, Andreas
van der Pol, W.

is schema:about of

named entity 'gene'
named entity 'genetic confirmation'
named entity 'clinical trial'
named entity 'gene therapy'
named entity 'SMA'
named entity 'copy number'
named entity 'intravenous'
named entity 'risk ratio'
named entity 'gene'
named entity 'Biogen'
named entity 'SMN2'
named entity 'EMA'
named entity 'Roche'
named entity 'nusinersen'
named entity 'advanced stages'
named entity 'mutation'
named entity 'SMA'
named entity 'oligonucleotide'
named entity 'Spinal muscular atrophy'
named entity 'disease-modifying'
named entity 'advanced stages'
named entity 'treatment of patients'
named entity 'SMA'
named entity 'SMA'
named entity 'Risdiplam'
named entity 'copy numbers'
named entity 'SMA'
named entity 'newborn screening'
named entity 'SMA'
named entity 'type 1'
named entity 'European Medicine Agency'
named entity 'motor neurons'
named entity 'Biogen'
named entity 'route of administration'
named entity 'dorsal ganglia'
named entity 'evolution'
named entity 'intrathecally'
named entity 'copy number'
named entity 'SMN2'
named entity 'biodistribution'
named entity 'risk-benefit ratio'
named entity 'disease outcome'
named entity 'Avexis'
named entity 'clinical trials'
named entity 'Roche'
named entity 'SMA'
named entity 'AveXis'
named entity 'Biogen'
named entity 'SMA'
named entity 'viral vector'
named entity 'muscle weakness'
named entity 'health systems'
named entity 'protein expression'
named entity 'copy number'
named entity 'SMA'
named entity 'Avexis'
named entity 'SMA'
named entity 'nusinersen'
named entity 'clinical trials'
named entity 'bi-allelic'
named entity 'clinical diagnosis'
named entity 'newborn screening'
named entity 'SMN'
named entity 'Roche'
named entity 'Biogen'
named entity 'long-term'
named entity 'biomarkers'
named entity 'clinical diagnosis'
named entity 'SMA'
named entity 'gene therapy'
named entity 'SMN1'
named entity 'Avexis'
named entity 'body weight'
named entity 'SMA'
named entity 'AveXis'
named entity 'REDCap'
named entity 'type 1'
named entity 'shared decision making'
named entity 'SMA'
named entity 'Onasemnogene abeparvovec'
named entity 'SMN1'
named entity 'body weight'
named entity 'Nusinersen'
named entity 'Palliative care'
named entity 'disability'
named entity 'pharmaceutical industry'
named entity 'SMN2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software